PSYCH 089: Opioid Use and Related Disorders: From Neuroscience to Treatment

Medlock Holmes enters a city built around a remarkable hospital.

Within its walls, suffering is eased. Pain is softened. Patients who could not move begin to breathe, walk, sleep, and recover. The medicines used here are powerful, ancient, and deeply valuable.

Yet beyond the hospital gates, Holmes finds another city forming in the shadows.

At first, the same medicines offer warmth, relief, and escape. Then tolerance develops. The dose that once brought comfort no longer works. The body adapts. The mind learns. The streets begin to reorganise around a single need: obtain the opioid, avoid withdrawal, and return to relief.

Holmes follows the trail from prescription tablets to heroin, from heroin to fentanyl, from private pain to public health crisis. He discovers that opioid use disorder is not simply a problem of pleasure-seeking. It is a chronic relapsing-remitting brain disorder involving reward, motivation, memory, stress, pain, attachment, and survival.

The neurobiology is central. Opioids act primarily through mu-opioid receptors, producing analgesia, euphoria, sedation, respiratory depression, and gastrointestinal effects. With repeated use, neural circuits adapt. Dopamine reward pathways are altered, stress systems become sensitised, and withdrawal becomes a powerful driver of continued use.

Holmes recognises withdrawal as the body’s alarm system in reverse. Anxiety, sweating, yawning, diarrhoea, muscle aches, insomnia, rhinorrhoea, piloerection, and craving emerge when opioid signalling falls. The person may no longer be using to feel high, but to feel briefly normal.

The greatest danger is overdose. Respiratory depression can silently turn sleep into coma. Fentanyl and other synthetic opioids make the margin between intoxication and death frighteningly narrow. Naloxone becomes the emergency key that can unlock the receptor and restore breathing, but it is only the beginning of treatment.

The real transformation comes through sustained care. Methadone, buprenorphine, and extended-release naltrexone each act differently at the opioid receptor, but all can reduce relapse, overdose, and mortality when properly used. Psychosocial treatment, trauma-informed care, family support, harm reduction, housing, employment, and recovery communities rebuild the wider city around the person.

By the end of the investigation, Holmes sees opioid treatment not as replacing one dependence with another, but as restoring biological stability so that choice, dignity, and future can return.

The mystery is not whether recovery is possible.

It is why society so often withholds the very treatments that make recovery more likely.

Key Takeaways

• Opioids include naturally occurring, semi-synthetic, and synthetic substances such as morphine, heroin, oxycodone, methadone, buprenorphine, and fentanyl.

• Opioid use disorder is a chronic relapsing-remitting condition involving brain reward, stress, memory, motivation, and control systems.

• Mu-opioid receptor activation produces analgesia, euphoria, sedation, miosis, constipation, and respiratory depression.

• Tolerance develops with repeated opioid exposure, often leading to escalating use.

• Withdrawal may include dysphoria, anxiety, muscle aches, nausea, vomiting, diarrhoea, sweating, yawning, rhinorrhoea, piloerection, insomnia, and craving.

• Opioid intoxication may present with euphoria followed by apathy, impaired judgement, drowsiness, slurred speech, miosis, and impaired attention or memory.

• Opioid overdose is a medical emergency characterised by coma, respiratory depression, and often pinpoint pupils.

• Naloxone reverses opioid overdose by antagonising opioid receptors and restoring ventilation.

• Fentanyl and other high-potency synthetic opioids have significantly increased overdose risk.

• Detoxification alone is not adequate treatment and may increase overdose risk if not followed by relapse-prevention care.

• Methadone is a full opioid agonist used in maintenance treatment.

• Buprenorphine is a partial opioid agonist with a ceiling effect that improves safety and can block other opioids.

• Naltrexone is an opioid antagonist used after detoxification to prevent relapse.

• Effective treatment combines medication, psychosocial interventions, harm reduction, medical care, and long-term recovery support.

• Comorbid depression, anxiety, PTSD, antisocial traits, chronic pain, hepatitis, HIV, and polysubstance use are common and require integrated care.